



# Cancer Immunotherapy Symposium

Session /Tuesday April 26th

**Chairman: Tito Fojo MD, PhD & Zaima Mazorra PhD**

		Speakers	Institution	Country	Modality
10:30	11:00	Tito Fojo. "Challenging existing paradigms in the therapy of cancer"	Columbia University	USA	Face to Face
11:00	11:30	Prof. István Peták. "AI-assisted treatment decisions in precision oncology"	Oncompass medicine	Hungary	Virtual
11:30	12:00	Susan Bates: "Pancreatic cancer- Leveraging the knowledge we have in 2022"	Columbia University	USA	Face to Face
12:00	12:30	Natasha Frank. "Immunological targeting of cancer stem cells"	Harvard Medical School	USA	Face to Face
12:30	13:00	Markus Frank. "Stem Cell-Mediated Therapeutic Immunomodulation"	Harvard Medical School	USA	Face to Face
13:00	13:30	Iraldo Bello. "HeberFERON in the treatment of non-melanoma skin cancer. Five years follow-up"	Center for Genetic Engineering and Biotechnology	Cuba	Face to Face
13:30	15:00	<b>Lunch</b>			

**Short oral presentations of selected posters**

**Chairman: Mayra Ramos PhD & Julio Raúl Fernández Massó PhD**

			Institution	Country	Modality
15:00	15:15	Claudia Martínez -Suárez. "Basal cell carcinoma treated with HeberFERON. A real world retrospective study"	Center for Genetic Engineering and Biotechnology,	Cuba	Face to Face
15:15	15:30	María Margarita Ríos Cabrera. "Use of a combination of alpha and gamma interferons in patients with advanced brain or kidney tumors without therapeutic options"	Arnaldo Milian Hospital	Cuba	Face to Face
15:30	15:45	Julio Raúl Fernández Massó. "Targeting NF-κB and HIF-1 pathways with CIGB-552 peptide"	Center for Genetic Engineering and Biotechnology	Cuba	Face to Face
15:45	16:00	Ana Cristina Campal Espinosa. "Outcomes of patients with advanced castration-sensitive prostate cancer 8 years after immunization with a GnRH-based therapeutic vaccine candidate"	Center for Genetic Engineering and Biotechnology	Cuba	Face to Face
16:00	16:15	Angel Casacó. "Analysis of different animal species for toxicological studies of biopharmaceuticals: The monoclonal study of nimotuzumab"	Center of Molecular Immunology	Cuba	Face to Face
16:15	16:30	Yamirka Sánchez Ascuy. "Safety and survival of patients treated with nimotuzumab concurrent with gemcitabine in the treatment of locally advanced or metastatic pancreatic adenocarcinoma"	III Congreso Hospital	Cuba	Face to Face
16:30	16:45	José Alert Silva. "Nimotuzumab combined with radiation therapy in the treatment of infiltrating and diffuse brain stem tumors in children and adolescents"	National Institute of Oncology and Radiobiology	Cuba	Face to Face
16:45	17:00	Mayra Ramos Suzarte. "Nimotuzumab in the treatment of tumors of epithelial origin: more than 20 years of experience"	Center of Molecular Immunology	Cuba	Face to Face

**Posters**

1.1	Yaimarelys Saumell Nápoles "Safety and survival of patients treated with nimotuzumab concurrent with gemcitabine in the treatment of locally advanced or metastatic pancreatic adenocarcinoma."	Center of Molecular Immunology	Cuba	
1.2	Angel Casacó. "Analysis of different animal species for toxicological studies of biopharmaceuticals: The monoclonal study of nimotuzumab"	Center of Molecular Immunology	Cuba	

1.3	José Alert Silva. "Nimotuzumab combined with radiation therapy in the treatment of infiltrating and diffuse brain stem tumors in children and adolescents"	National Institute of Oncology and Radiobiology	Cuba	
1.4	Mayra Ramos Suzarte. "Nimotuzumab in the treatment of tumors of epithelial origin: more than 20 years of experience"	Center of Molecular Immunology	Cuba	
1.5	Mayelin Troche Concepcion "Efficacy and safety of Nimotuzumab in two clinical studies of non-small cell lung cancer"	Center of Molecular Immunology	Cuba	
1.6	Alexis Álvarez Lobaina "Treatment and survival of patients with melanoma at the National Institute of Oncology and Radiobiology"	Center of Molecular Immunology	Cuba	
1.7	Yanelda Garcia Vega "Immunotherapy of oncodermatological diseases"	Center of Molecular Immunology	Cuba	
1.8	Claudia Martínez -Suárez. "Basal cell carcinoma treated with HeberFERON. A real world retrospective study"	Center for Genetic Engineering and Biotechnology	Cuba	
1.9	María Margarita Ríos Cabrera. "Use of a combination of alpha and gamma interferons in patients with advanced brain or kidney tumors without therapeutic options"	Arnaldo Milian Hospital	Cuba	
1.10	Julio Raúl Fernández Massó. "Targeting NF-κB and HIF-1 pathways with CIGB-552 peptide"	Center for Genetic Engineering and Biotechnology	Cuba	
1.11	Ana Cristina Campal Espinosa. "Outcomes of patients with advanced castration-sensitive prostate cancer 8 years after immunization with a GnRH-based therapeutic vaccine candidate"	Center for Genetic Engineering and Biotechnology	Cuba	
1.12	María Mercedes Vázquez. "Active PharmacoSurrveillance Study of HeberFERON® in Basal Cell Carcinoma and COVID-19"	Center for Genetic Engineering and Biotechnology	Cuba	
1.13	Belkis Romeu "CECMED Innovation Office: an initiative to promote the development of novel biopharmaceutical products"	State Center for the Control of Drugs, Equipment and Electronic Devices	Cuba	

**Session/ Wednesday April 27th**

<b>Chairman: Francesco Ferrucci MD PhD &amp; Circe Mesa PhD</b>					
		<b>Speakers</b>	<b>Institution</b>	<b>Country</b>	<b>Modality</b>
09:00	09:30	Franco Cavalli. "The role of immunotherapy in the treatment of malignant lymphomas"	Institute of Oncology of Southern Switzerland	Switzerland	Face to Face
09:30	10:00	Sattva S. Neelapu. "CAR T-cell therapy for lymphoma"	The University of Texas M.D. Anderson Cancer Center	USA	Virtual
10:00	10:30	Kalet Leon. "Human IL-2 mutein for cancer immunotherapy"	Center of Molecular Immunology	Cuba	Face to Face
10:30	11:00	Christophe Massard. "From PD1/PDL1 to precision immunotherapy in early clinical trials"	Institute Gustave Roussy	France	Virtual
11:00	11:15	<b>Coffee Break</b>			
11:15	11:45	Francesco Ferrucci. "Neoadjuvant ipilimumab/nivolumab in locally advanced melanoma: clinical results and immunological biomarker's analysis"	European Institute of Oncology	Italy	Face to Face
11:45	12:15	Michael Olin. "Use of Single Peptide Checkpoint Inhibitor in the Treatment of Adult Recurrent Glioblastoma"	University of Minnesota	USA	Face to Face
12:15	12:45	Avery Posey. "Exploiting truncated O-glycosylation in tumours for immunotherapy"	University of Pennsylvania	USA	Virtual
12:45	13:15	Circe Mesa: "Changing the balance between good and bad myeloid cells using a Very Small Size Particles (VSSP)"	Center of Molecular Immunology/Innovative Immunotherapy Alliance	Cuba	Face to Face
13:15	15:00	<b>Lunch</b>			
<b>Short oral presentations of selected posters</b>					
<b>Chairman: Tays Hernández PhD &amp; Tania Carmenate PhD</b>					
			<b>Institution</b>	<b>Country</b>	<b>Modality</b>

15:00	15:15	Camila Canaán-Haden Ayala "A novel PDL1-targeted vaccine elicits humoral and cellular immunity for cancer immunotherapy"	Center for Genetic Engineering and Biotechnology	Cuba	Face to Face
15:15	15:30	Cynthia González-Muñoz. "First evidences of the use of Itolizumab as a potential anti-checkpoint inhibitor for the treatment of cancer patients and as treatment opportunity for multiple sclerosis patients"	Center of Molecular Immunology	Cuba	Face to Face
15:30	15:45	Liliana Oliver. "Mitigating the Prevalence and Function of Myeloid-Derived Suppressor Cells by Redirecting Myeloid Differentiation Using a Novel Immune Modulator"	Center of Molecular Immunology	Cuba	Face to Face
15:45	16:00	Orlando Valdés. "Ganglioside containing nanoparticles: a novel approach to reprogram tumor-altered myeloid compartment and overcome immunosuppression in breast cancer patients"	National Institute of Oncology and Radiobiology	Cuba	Face to Face
16:00	16:15	Jorge Soriano "Effect of conventional chemotherapy regimens on circulating myeloid immune cells in patients with solid tumors"	Hermanos Ameijeiras Hospital	Cuba	Face to Face
16:15	16:30	Janoi Chang. "PEGylation strategy for improved the antitumoral activity of the IL-2 mutant no alpha"	Center of Molecular Immunology	Cuba	Face to Face
16:30	16:45	Ana Victoria Casadesus. "A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy"	Center of Molecular Immunology	Cuba	Face to Face
16:45	17:00	Tays Hernández. "Moving towards better anti-CD20 therapies through the use of optimized IL-2 based immunocytokines"	Center of Molecular Immunology	Cuba	Face to Face
<b>Posters</b>					
2.1		Liliana Oliver. "Mitigating the Prevalence and Function of Myeloid-Derived Suppressor Cells by Redirecting Myeloid Differentiation Using a Novel Immune Modulator"	Center of Molecular Immunology	Cuba	
2.2		Rydell Alvarez. "Macrophage functional programming by immunomodulatory very small size particles (VSSP)"	Center of Molecular Immunology	Cuba	
2.3		Orlando Valdés. "Ganglioside containing nanoparticles: a novel approach to reprogram tumor-altered myeloid compartment and overcome immunosuppression in breast cancer patients"	National Institute of Oncology and Radiobiology	Cuba	
2.4		Jorge Soriano "Effect of conventional chemotherapy regimens on circulating myeloid immune cells in patients with solid tumors"	Hermanos Ameijeiras Hospital	Cuba	
2.5		Daylen Aguilar Noriega "Pharmacological inhibition of the protein kinase 2 modulates PD-L1 levels in non-small cell lung cancer cell lines"	Center for Genetic Engineering and Biotechnology	Cuba	
2.6		Camila Canaán-Haden Ayala "A novel PDL1-targeted vaccine elicits humoral and cellular immunity for cancer immunotherapy"	Center for Genetic Engineering and Biotechnology	Cuba	
2.7		Cynthia González-Muñoz. "First evidences of the use of Itolizumab as a potential anti-checkpoint inhibitor for the treatment of cancer patients and as treatment opportunity for multiple sclerosis patients"	Center of Molecular Immunology	Cuba	
2.8		Anabel Lavastida Linares. "Characterization of immune infiltrating cells from different solid tumors (preliminary results)"	Center of Molecular Immunology	Cuba	
2.9		Javier Sánchez Ramírez. "Characteristics of the specific humoral immune response after active immunotherapy with a VEGF vaccine. An overview of the results from three trials in cancer patients"	Center for Genetic Engineering and Biotechnology	Cuba	
2.10		Carmen Viada. "Relationship of inflammation indexes with survival in cancer".	Center of Molecular Immunology	Cuba	
2.11		Janoi Chang. "PEGylation strategy for improved the antitumoral activity of the IL-2 mutant no alpha"	Center of Molecular Immunology	Cuba	
2.12		Ana Victoria Casadesus. "A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy"	Center of Molecular Immunology	Cuba	
2.13		Tays Hernández. "Moving towards better anti-CD20 therapies through the use of optimized IL-2 based immunocytokines"	Center of Molecular Immunology	Cuba	

**Session/ Thursday April 28th**

**Chairman: Mary Reid MD, PhD & Tania Crombet MD, PhD**

		<b>Speakers</b>	<b>Institution</b>	<b>Country</b>	<b>Modality</b>
09:00	09:30	Mary Reid: "The Potential Role for EGF-depleting Immunotherapy for the Prevention of Lung Cancer Development or Recurrence"	Roswell Park Comprehensive Cancer Center	USA	Face to Face
09:30	10:00	Tania Crombet Ramos. "Cimavax-EGF in the real-world scenario"	Center of Molecular Immunology	Cuba	Face to Face
10:00	10:30	Grace Dy. "CIMAvax-EGF in Combination with Nivolumab in Advanced Stage NSCLC"	Roswell Park Comprehensive Cancer Center	USA	Virtual
10:30	11:00	Delvys Rodríguez-Abreu. "The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC"	Maternal and Child University Hospital Complex of the Gran Canaria Island	Spain	Face to Face
11:00	11:15	<b>Coffee Break</b>			
11:15	11:45	Belinda Sanchez-Ramírez. "Cancer vaccines based on HER oncogenes"	Center of Molecular Immunology	Cuba	Face to Face
11:45	12:15	Jesus Junco. "GnRH-Based Vaccine Candidate Directed to Prostate Cancer"	Center for Genetic Engineering and Biotechnology	Cuba	Face to Face
12:15	12:45	Alexei Fedorovich Licea Navarro. "Isolation of "Nanobodies" and rational design of "Picobodies" for immunotherapy of solid tumors"	Center for Scientific Research and Higher Education of Ensenada	Mexico	Face to Face
12:45	13:15	David A. Largaespada. "Viral and NK cell therapy for peripheral nerve sheath tumors"	Unniversity of Minnesota	USA	Virtual
13:15	15:00	<b>Lunch</b>			

**Short oral presentations of selected posters**

**Chairman: Belinda Sánchez PhD & Orestes Santos MD**

			<b>Institution</b>	<b>Country</b>	<b>Modality</b>
15:00	15:15	Ramón Alberto Ortiz Carrodeguas. "Introduction of Cuban immunotherapies for the treatment of lung cancer in Villa Clara Province. A Population-based outcomes study in 2001-2019 period."	Celestino Hernández Hospital	Cuba	Face to Face
15:15	15:30	Raiza Ruiz Lorente. "Specific immunotherapy in cervical-uterine cancer with the CIMAvax-EGF vaccine and the monoclonal antibody nimotuzumab"	Ramón González Coro Hospital	Cuba	Face to Face
15:30	15:45	Soraida Acosta Brooks. "Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF"	Saturnino Lora Hospital	Cuba	Face to Face
15:45	16:00	Elia Neninger. "Long-term survival in advanced NSCLC treated with Cimavax EGF vaccine after switch maintenance and in combination with first- line chemotherapy"	Hermanos Ameijeiras Hospital	Cuba	Face to Face
16:00	16:15	Orestes Santos. "CIMAvax-EGF improves survival in advanced NSCLC patients not progressing after first line platinum-based chemotherapy and basal sEGF concentration above 870pg/mL"	Center of Molecular Immunology	Cuba	Face to Face
16:15	16:30	Jennysbel de la C Hernández. "Immune response in COPD patients after vaccination with CIMAvax-EGF in a preventive scenario"	Center of Molecular Immunology	Cuba	Face to Face
16:30	16:45	Sailyn Alfonso Alemán. "Long term survival in patients whit advanced NSCLC treated whit racotumumab in switch maintenance: cases report"	Celestino Hernández Hospital	Cuba	Face to Face
16:45	17:00	Gretchen Bergado. "Downregulation of HER1 and HER2 induced by polyclonal antibodies and their impact on tumor cells hallmarks in the context of activating mutations in HER1 and KRas"	Center of Molecular Immunology	Cuba	Face to Face

**Posters**

3.1	Ramón Alberto Ortiz Carrodeguas. "Introduction of Cuban immunotherapies for the treatment of lung cancer in Villa Clara Province. A Population-based outcomes study in 2001-2019 period."	Celestino Hernández Hospital	Cuba	
3.2	Elena García López. "Quality of life in patients with non-small cell lung cancer treated with the combination of CIMAvax® EGF and Racotumomab"	National Coordinating Center for Clinical Trials	Cuba	
3.3	Pedro Pablo Guerra Chaviano. "Organizational strategy for the administration of the CIMAvax-EGF® vaccine in Primary Health Care"	National Coordinating Center for Clinical Trials	Cuba	

3.4	Geidy Lorenzo. "Survival of advanced NSCLC patients treated with CIMAvax-EGF in real-world setting: evaluation of the effectiveness related to basal EGF concentrations"	Center of Molecular Immunology	Cuba	
3.5	Yoanna Flores. "Survival of NSCLC patients treated with CIMAVAX-EGF as maintenance therapy in the real-world scenario"	National Institute of Oncology and Radiobiology	Cuba	
3.6	Raiza Ruiz Lorente. "Specific immunotherapy in cervical-uterine cancer with the CIMAvax-EGF vaccine and the monoclonal antibody nimotuzumab"	Ramón González Coro Hospital	Cuba	
3.7	Soraida Acosta Brooks. "Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF"	Saturnino Lora Hospital	Cuba	
3.8	Elia Neninger. "Long-term survival in advanced NSCLC treated with Cimavax EGF vaccine after switch maintenance and in combination with first- line chemotherapy"	Hermanos Ameijeiras Hospital	Cuba	
3.9	Orestes Santos. "CIMAvax-EGF improves survival in advanced NSCLC patients not progressing after first line platinum-based chemotherapy and basal sEGF concentration above 870pg/mL"	Center of Molecular Immunology	Cuba	
3.10	Jennysbel de la C Hernández. "Immune response in COPD patients after vaccination with CIMAvax-EGF in a preventive scenario"	Center of Molecular Immunology	Cuba	
3.11	Sailyn Alfonso Alemán. "Long term survival in patients whit advanced NSCLC treated whit racotumumab in switch maintenance: cases report"	Celestino Hernández Hospital	Cuba	
3.12	Haslen H Caceres-Lavernia. "Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment"	Hermanos Ameijeiras Hospital	Cuba	
3.13	Kirenia Camacho Sosa. "Survival of patients with non-small cell lung cancer treated with Cuban immunotherapy. Matanzas 2012-2021"	Faustino Pérez Hospital	Cuba	
3.14	Gretchen Bergado. "Downregulation of HER1 and HER2 induced by polyclonal antibodies and their impact on tumor cells hallmarks in the context of activating mutations in HER1 and KRas"	Center of Molecular Immunology	Cuba	

**Session/ Friday April 29th**

**Chairman: Arjan Willen Griffioen MD, PhD & Yanelys Morera PhD**

		<b>Speakers</b>	<b>Institution</b>	<b>Country</b>	<b>Modality</b>
09:00	09:30	James P. Allison: Nobel Prize in Physiology or Medicine, 2018	The University of Texas MD Anderson Cancer Center	USA	Virtual
09:30	10:00	Aldo Venutti. "In situ vaccination: the new frontier of immunotherapy for HPV-associated cancer"	IRCCS Regina Elena National Cancer Institute	Italy	Face to Face
10:00	10:30	Karen Anderson. "The Structural Basis for T cell Epitope Selection for Cancer Immunotherapy"	Arizona State University	USA	Virtual
10:30	11:00	Arjan Willem Griffioen. "A vaccination approach against the tumor vasculature"	Free University of Amsterdam	Netherlands	Face to Face
11:00	11:15	<b>Coffee Break</b>			
11:15	11:45	Yanelys Morera-Diaz. "Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: Development and perspectives"	Center for Genetic Engineering and Biotechnology	Cuba	Face to Face
11:45	12:15	Monica Bequet. "Impact of HEBER-SaVax in the tumor microenvironment"	Center for Genetic Engineering and Biotechnology	Cuba	Face to Face
12:15	12:45	Oscar Arrieta. "Cancer Immunotherapy beyond PD1"	Instituto Nacional de Cancerología	Mexico	Face to Face
12:45	15:00	<b>Lunch</b>			